Purexa Process 50 NAEX Now Available for Commercial Manufacturing
Donaldson Life Sciences is pleased to announce the commercial launch of the Purexa™ Process 50 NAEX 3μm membrane chromatography device, now available for manufacturing-scale pDNA purification.
Designed for the capture step in plasmid DNA workflows, Purexa NAEX products feature a weak anion-exchange membrane that delivers high binding capacity for supercoiled pDNA while maintaining fast processing times and consistent recovery.
Purexa NAEX launched in the Prep (≤ 0.3 mL) form factor in 2025. With the introduction of the Process 50 (40-50 mL, stackable up to 250 mL) form factor, teams can now scale this chemistry into manufacturing environments with confidence. Manufacturing-grade devices are available, supporting the transition from process development to production without changing platform or performance expectations.
Built for Scalable pDNA Capture
Purexa NAEX plays a critical role in pDNA purification by enabling efficient capture of plasmid DNA early in the workflow. When paired with downstream polishing using Purexa MCP, the platform supports high-purity outcomes across applications.
Key benefits include:
High binding capacity for supercoiled pDNA
Fast cycle times, typically under 15 minutes
Successful removal of stubborn impurities including endotoxins, HCPs, and gDNA
Scalable performance from development to manufacturing
Expand Your Process Development with Process 50
In addition to NAEX for pDNA capture, the Process 50 form factor is also available in engineering grade for:
This supports the use of multiple membrane chemistries in a scalable format, enabling seamless integration into manufacturing workflows.
Available Now
The Purexa Process 50 NAEX device is now available for order as part of the growing Purexa membrane chromatography portfolio.
To place an order or learn more, contact us.
